International Journal of Clinical Research

Objective: To explore the effects of prophylactic anticoagulation with low molecular weight heparin(LMWH) and starting administration at different times on patients with lung cancer surgery. Methods: 180 lung cancer patients who underwent surgical treatment in our hospital from September 2020 to December 2021 were selected and divided into the preoperative anticoagulant group (n=43), the postoperative anticoagulant group (n=79) and the non-anticoagulant group (n=58) according the use of anticoagulant drugs. The intraoperative and postoperative clinical indicators including operative time, intraoperative bleeding, postoperative drainage tube indwelling time, postoperative chest volume and postoperative hospital stay and the incidence of thrombotic disease after surgery were compared among the three groups. Thromboelastogram was examined before surgery and on the 1st, 2nd, 3rd, 4th and 5th day after surgery. Results: On the 1st, 2nd, 3rd, 4th and 5th day after operation, there was significant difference in R value among preoperative anticoagulation group, postoperative anticoagulation group and non-anticoagulation group. There was no significant difference between the other indicators(P＞0.05). The incidence of postoperative thrombotic diseases in the preoperative and postoperative anticoagulant group was lower than that in the non-anticoagulant group (P＜0.05). There was no significant difference in the incidence of postoperative thrombotic diseases between preoperative anticoagulant group and postoperative anticoagulant group(P＞0.05). Conclusion: The use of low-molecular-weight heparin prophylactic anticoagulation therapy can reduce the risk of postoperative venous thrombosis in patients with lung cancer. The clinical value of preoperative or postoperative prophylactic anticoagulation is equivalent.

Lung cancer; low molecular weight heparin; anticoagulation; Venous thromboembolism